货号:A1467731 同义名: Vepdegestrant
ARV-471是一种雌激素受体(estrogen receptor, ER) PROTAC 蛋白降解剂,能有效去除 ER+ 乳腺癌细胞中的雌激素受体。它在乳腺癌治疗研究中具有潜在应用。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Vepdegestrant (ARV-471) serves as an orally active PROTAC estrogen receptor degrader designed for breast cancer treatment. It facilitates interactions between estrogen receptor alpha and an intracellular E3 ligase complex, leading to ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant effectively degrades ER in ER-positive breast cancer cell lines, with a half-maximal degradation concentration (DC50) of approximately 2 nM [1]. |
体内研究 | Vepdegestrant inhibits tumor growth in estradiol-dependent MCF7 xenografts and reduces tumor ER protein levels when administered orally at doses ranging from 3 to 30 mpk once daily [2]. |
体外研究 | Vepdegestrant (10 and 100 nM, 3 days) enhances MHC-I expression in MCF7 cells harboring the Y537S mutation in the estrogen receptor (ER-Y537S) [3]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.38mL 0.28mL 0.14mL |
6.91mL 1.38mL 0.69mL |
13.81mL 2.76mL 1.38mL |
CAS号 | 2229711-68-4 |
分子式 | C45H49N5O4 |
分子量 | 723.9 |
别名 | Vepdegestrant |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Inert atmosphere,2-8°C |
溶解度 |
DMSO: 105 mg/mL(145.05 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |